Gender Matters. Sex-related Differences in Immunotherapy Outcome in Patients with Non-small Cell Lung Cancer

Title:Gender Matters. Sex-related Differences in Immunotherapy Outcome in Patients with Non-small Cell Lung Cancer

Volume: 24

Author(s): Enrico Caliman, Maria Cristina Petrella, Virginia Rossi, Francesca Mazzoni, Anna Maria Grosso, Sara Fancelli, Luca Paglialunga, Camilla Comin, Giandomenico Roviello, Serena Pillozzi and Lorenzo Antonuzzo*

Affiliation:

• Medical Oncology Unit, Careggi University Hospital, Florence, Italy
• Department of Experimental and Clinical Medicine, University of Florence, Italy

Keywords: non-small cell lung cancer, gender, immunotherapy, gender-medicine, sex differences, immune-checkpoint inhibitors

Abstract: Background: Emerging evidence identified sex as a variable regulating immune system functions and modulating response to immunotherapy in cancer patients.

Objective: This retrospective study analysed sex-related differences in immunotherapy outcomes in a real-world population of non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).

Methods: We retrospectively investigated clinical data of 99 patients with advanced NSCLC and treated with single-agent nivolumab and pembrolizumab at Medical Oncology Unit, Careggi University Hospital, Florence (Italy), between April 2014 to August 2019. Main clinical characteristics and clinical outcomes were analysed.

Results: Our study showed that the efficacy of ICI treatment differed according to gender. A trend for better median progression-free survival (mPFS) was reported in males (mPFS 5.0 months, 95% Confidence Interval [CI] 4.0-11.0) than females (mPFS 4.5 months, 95% CI 2.0-9.0) (p=0.133), while no significant difference for overall survival (OS) between the two sex groups was observed (p=0.622). In the nivolumab cohort, we showed a statistically significant difference for a longer PFS in men compared to women (log-rank p=0.054), HR for PFS in females versus males was 1.81 (95% CI 0.97- 3.37, p=0.062). Disease control rate (DCR) was achieved in 55.7% and 45.7% of men and women, respectively, while disease progression was registered in 44.3% of males and 54.3% of females (p=0.386).

Conclusion: Gender is a variable that should be taken into account in the choice of immunotherapy. Future prospective randomized trials testing tailored sex-based immunotherapy strategies are required to validate our findings before integrating into clinical practice.

Cite this article as:

Caliman Enrico, Petrella Cristina Maria, Rossi Virginia, Mazzoni Francesca, Grosso Maria Anna, Fancelli Sara, Paglialunga Luca, Comin Camilla, Roviello Giandomenico, Pillozzi Serena and Antonuzzo Lorenzo*, Gender Matters. Sex-related Differences in Immunotherapy Outcome in Patients with Non-small Cell Lung Cancer, Current Cancer Drug Targets 2024; 24 () . https://dx.doi.org/10.2174/1568009622666220831142452